Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 13, 2014, 53 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $124.00 to $10,468,812.92.

Highlighted Stocks Traded by Insiders:

Nordson Corporation (NDSN) - FREE Research Report

Lambert Peter who is Senior Vice President at Nordson Corporation sold 2,000 shares at $71.56 on Jan. 13, 2014. Following this transaction, the Senior Vice President owned 25,558 shares meaning that the stake was reduced by 7.26% with the 2,000-share transaction.

The shares most recently traded at $70.71, down $0.85, or 1.2% since the insider transaction. Historical insider transactions for Nordson Corporation go as follows:

  • 4-Week # shares sold: 5,412
  • 12-Week # shares sold: 5,412
  • 24-Week # shares sold: 6,405

The average volume for Nordson Corporation has been 215,300 shares per day over the past 30 days. Nordson Corporation has a market cap of $4.6 billion and is part of the industrial goods sector and industrial industry. Shares are down 4.62% year-to-date as of the close of trading on Monday.

Nordson Corporation engineers, manufactures, and markets products and systems for dispensing and processing adhesives, coatings, polymers, sealants, biomaterials, fluid management, testing and inspection, surface treatment, and curing. The stock currently has a dividend yield of 1%. The company has a P/E ratio of 21.1. Currently there are no analysts that rate Nordson Corporation a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NDSN - FREE

TheStreet Quant Ratings rates Nordson Corporation as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Nordson Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Finisar Corporation (FNSR) - FREE Research Report

Adzema Kurt who is Chief Financial Officer at Finisar Corporation sold 205 shares at $24.90 on Jan. 13, 2014. Following this transaction, the Chief Financial Officer owned 96,205 shares meaning that the stake was reduced by 0.21% with the 205-share transaction.

The shares most recently traded at $23.63, down $1.27, or 5.37% since the insider transaction. Historical insider transactions for Finisar Corporation go as follows:

  • 4-Week # shares sold: 14,540
  • 12-Week # shares sold: 18,510
  • 24-Week # shares sold: 431,489

The average volume for Finisar Corporation has been 2.6 million shares per day over the past 30 days. Finisar Corporation has a market cap of $2.3 billion and is part of the technology sector and computer hardware industry. Shares are down 2.05% year-to-date as of the close of trading on Monday.

Finisar Corporation provides optical subsystems and components for data communication and telecommunication applications in the United States, Malaysia, China, and internationally. The company has a P/E ratio of 42.6. Currently there are 9 analysts that rate Finisar Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FNSR - FREE

TheStreet Quant Ratings rates Finisar Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Finisar Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NuVasive (NUVA) - FREE Research Report

Lukianov Alexis V who is Chairman & CEO at NuVasive sold 4,800 shares at $35.16 on Jan. 13, 2014. Following this transaction, the Chairman & CEO owned 50,940 shares meaning that the stake was reduced by 8.61% with the 4,800-share transaction.

The shares most recently traded at $33.95, down $1.21, or 3.57% since the insider transaction. Historical insider transactions for NuVasive go as follows:

  • 4-Week # shares sold: 48,346
  • 12-Week # shares sold: 84,234
  • 24-Week # shares sold: 121,881

The average volume for NuVasive has been 445,800 shares per day over the past 30 days. NuVasive has a market cap of $1.6 billion and is part of the health care sector and health services industry. Shares are up 4.79% year-to-date as of the close of trading on Monday.

NuVasive, Inc., a medical device company, engages in the design, development, and marketing of minimally disruptive surgical products and procedurally integrated solutions for the spine. The company's products focus on applications for spine fusion surgery. Currently there are 7 analysts that rate NuVasive a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NUVA - FREE

TheStreet Quant Ratings rates NuVasive as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full NuVasive Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Deckers Outdoor Corporation (DECK) - FREE Research Report

Rishwain Constance who is President UGG and Tsubo at Deckers Outdoor Corporation sold 7,442 shares at $89.00 on Jan. 13, 2014. Following this transaction, the President UGG and Tsubo owned 111,419 shares meaning that the stake was reduced by 6.26% with the 7,442-share transaction.

The shares most recently traded at $85.79, down $3.21, or 3.74% since the insider transaction. Historical insider transactions for Deckers Outdoor Corporation go as follows:

  • 4-Week # shares sold: 9,387
  • 12-Week # shares sold: 50,687
  • 24-Week # shares sold: 55,764

The average volume for Deckers Outdoor Corporation has been 1.4 million shares per day over the past 30 days. Deckers Outdoor Corporation has a market cap of $3.1 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 0.97% year-to-date as of the close of trading on Monday.

Deckers Outdoor Corporation engages in the design, manufacture, and marketing of footwear and accessories for outdoor activities and casual lifestyle use for men, women, and children in the United States and internationally. The company has a P/E ratio of 31.9. Currently there are 7 analysts that rate Deckers Outdoor Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DECK - FREE

TheStreet Quant Ratings rates Deckers Outdoor Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Deckers Outdoor Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Neurocrine Biosciences (NBIX) - FREE Research Report

Gorman Kevin Charles who is President and CEO at Neurocrine Biosciences sold 3,750 shares at $18.57 on Jan. 13, 2014. Following this transaction, the President and CEO owned 180,952 shares meaning that the stake was reduced by 2.03% with the 3,750-share transaction.

OBrien Christopher Flint who is Chief Medical Officer at Neurocrine Biosciences sold 6,750 shares at $18.88 on Jan. 13, 2014. Following this transaction, the Chief Medical Officer owned 96,544 shares meaning that the stake was reduced by 6.53% with the 6,750-share transaction.

Coughlin Timothy P who is Chief Financial Officer at Neurocrine Biosciences sold 1,750 shares at $18.56 on Jan. 13, 2014. Following this transaction, the Chief Financial Officer owned 97,874 shares meaning that the stake was reduced by 1.76% with the 1,750-share transaction.

Bozigian Haig P. who is Chief Development Officer at Neurocrine Biosciences sold 1,625 shares at $18.58 on Jan. 13, 2014. Following this transaction, the Chief Development Officer owned 78,579 shares meaning that the stake was reduced by 2.03% with the 1,625-share transaction.

Grigoriadis Dimitri E. who is Chief Research Officer at Neurocrine Biosciences sold 1,625 shares at $18.56 on Jan. 13, 2014. Following this transaction, the Chief Research Officer owned 77,058 shares meaning that the stake was reduced by 2.07% with the 1,625-share transaction.

Gano Kyle who is Chief Business Dev Officer at Neurocrine Biosciences sold 1,250 shares at $18.57 on Jan. 13, 2014. Following this transaction, the Chief Business Dev Officer owned 23,738 shares meaning that the stake was reduced by 5% with the 1,250-share transaction.

The shares most recently traded at $19.10, up $0.53, or 2.77% since the insider transaction. Historical insider transactions for Neurocrine Biosciences go as follows:

  • 4-Week # shares sold: 233,000
  • 12-Week # shares sold: 233,000
  • 24-Week # shares sold: 315,531

The average volume for Neurocrine Biosciences has been 1.0 million shares per day over the past 30 days. Neurocrine Biosciences has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 99.68% year-to-date as of the close of trading on Monday.

Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Currently there are 11 analysts that rate Neurocrine Biosciences a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBIX - FREE

TheStreet Quant Ratings rates Neurocrine Biosciences as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Neurocrine Biosciences Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Doug Jones, Donald Trump and Janet Yellen - 5 Things You Must Know

Doug Jones, Donald Trump and Janet Yellen - 5 Things You Must Know

4 Signs the Bull Market in Stocks Remains Incredibly Strong

4 Signs the Bull Market in Stocks Remains Incredibly Strong

Why the World Isn't Ending: Market Recon

Why the World Isn't Ending: Market Recon

Cramer: Are You Paying Attention to These Boring Companies? You Should

Cramer: Are You Paying Attention to These Boring Companies? You Should